Skip to main content
. 2019 Oct 31;11:9307–9319. doi: 10.2147/CMAR.S213051

Figure 1.

Figure 1

Consort diagram and listing of reasons for early Ra223 discontinuation. One hundred and six of 198 patients (53.5%) did not receive 6 cycles of Ra223, and disease progression was the most common reason for early treatment discontinuation in those patients.